menu

CME: IBS-D: The Role of Pathophysiology in Assessment and Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

IBS-D: The Role of Pathophysiology in Assessment and Treatment

IBS-D: The Role of Pathophysiology in Assessment and Treatment
RestartResume
This case study focuses on screening methods and underlying cause of IBS-D symptoms to facilitate individualized treatment.

Available credits: 0.50

Time to complete: 30 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Patients with IBS-D may spend years before they are accurately diagnosed, with their symptoms often being labeled as psychosomatic. Considering the potential underlying cause of IBS-D can help guide diagnosis as well as the choice of appropriate treatment. In this activity, clinicians will learn screening methods and factors in the pathophysiology of IBS-D to more accurately diagnosis patients and select appropriate treatment, along with patient-clinician communication strategies that can improve outcomes.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty
    Jeffrey B. Danzig, MD, has disclosed that he has served on the speakers bureaus for Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals Inc., and Valeant Pharmaceuticals.

    Reviewers/Planners

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD, CHCP, has nothing to disclose.
    • Mary J. Krey has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.

    • Wendee Theilemann has nothing to disclose.

    Disclosure of Unlabeled Use

    This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products.

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
    antispasmodics, tricyclics, selective serotonin reuptake inhibitors, 5HT3 antagonists, serum-derived bovine immunoglobulin.

  • Intended Audience

    The intended audience for this activity is gastroenterologists and primary care providers.

  • Learning Objectives

    After completing this activity, the participant will be better able to:

    • Use established screening and detection methods to identify patients who have IBS-D symptoms
    • Explain considerations in selecting effective treatment for IBS-D, including the role of microbiota management
    • Employ patient-clinician communication strategies that encourage patients to share and describe their symptoms
  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Omnia-Prova Education Collaborative (TOPEC) and MedEdCom. TOPEC is accredited by the ACCME to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    This activity is jointly provided by The Omnia-Prova Education Collaborative (TOPEC) and MedEdCom.

  • Commercial Support

    This activity is supported by an independent educational grant from Salix Pharmaceuticals, Inc.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.